Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

XBiotech initiates phase II study of bermekimab in systemic sclerosis

Oct. 3, 2019

New registrational study evaluates miransertib in Proteus syndrome and PROS

Oct. 2, 2019

TLC initiates phase III pivotal EXCELLENCE study of TLC-599

Oct. 2, 2019

Development and characterization of IRAK-4 inhibitors

Sep. 30, 2019

Inflazome begins first-in-human study of IZD-334 for CAPS

Sep. 27, 2019

Positive topline results presented from phase II STAR study of tolperisone

Sep. 25, 2019

Phase III PREVENT trial of Cosentyx in nr-axSpA meets 16-week primary endpoint

Sep. 17, 2019

DSMC recommends continuation of U.S. study of IDCT for degenerative disc disease

Sep. 17, 2019

BoNTANA Therapies describes nucleic acids encoding botulinum neurotoxins

Sep. 13, 2019

Genentech describes lead small-molecule IRAK-4 inhibitors

Sep. 9, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...